Your browser is no longer supported. Please, upgrade your browser.
Settings
ELOX Eloxx Pharmaceuticals, Inc. daily Stock Chart
ELOX [NASD]
Eloxx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.16 Insider Own11.18% Shs Outstand40.13M Perf Week-12.76%
Market Cap95.76M Forward P/E- EPS next Y-0.83 Insider Trans0.00% Shs Float35.66M Perf Month-22.63%
Income-46.30M PEG- EPS next Q-0.20 Inst Own52.60% Short Float4.06% Perf Quarter-16.50%
Sales- P/S- EPS this Y8.10% Inst Trans0.07% Short Ratio17.60 Perf Half Y29.08%
Book/sh0.51 P/B4.96 EPS next Y12.60% ROA-86.60% Target Price- Perf Year-44.03%
Cash/sh0.98 P/C2.58 EPS next 5Y- ROE-144.80% 52W Range1.44 - 8.16 Perf YTD-65.63%
Dividend- P/FCF- EPS past 5Y44.90% ROI- 52W High-67.69% Beta2.49
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low83.12% ATR0.24
Employees29 Current Ratio3.60 Sales Q/Q- Oper. Margin- RSI (14)42.77 Volatility10.86% 8.51%
OptionableYes Debt/Eq0.68 EPS Q/Q50.70% Profit Margin- Rel Volume0.42 Prev Close2.53
ShortableYes LT Debt/Eq0.43 EarningsAug 06 AMC Payout- Avg Volume82.18K Price2.64
Recom2.00 SMA20-7.02% SMA50-12.66% SMA200-25.00% Volume26,729 Change4.23%
Jun-11-20Downgrade Citigroup Buy → Neutral
Sep-06-19Initiated Janney Buy $14
Dec-24-18Initiated H.C. Wainwright Neutral $10
Jul-03-18Initiated Citigroup Buy
Sep-14-20 10:06AM  
Aug-26-20 07:30AM  
Aug-12-20 07:30AM  
Aug-06-20 07:30AM  
Aug-04-20 07:30AM  
Jul-28-20 12:33PM  
Jul-21-20 02:17PM  
Jul-17-20 12:37PM  
Jul-15-20 01:08PM  
Jun-18-20 11:14AM  
10:42AM  
Jun-17-20 04:01PM  
Jun-11-20 12:06PM  
May-27-20 12:48PM  
May-08-20 03:01PM  
May-07-20 04:01PM  
Apr-21-20 12:37PM  
Apr-20-20 09:24AM  
Apr-13-20 07:30AM  
Apr-06-20 10:53AM  
Mar-25-20 09:00AM  
Mar-10-20 01:45PM  
Mar-05-20 04:00PM  
02:30PM  
Feb-26-20 04:00PM  
Jan-14-20 02:30PM  
Dec-27-19 06:38AM  
Dec-24-19 07:45AM  
Dec-22-19 06:41PM  
Dec-18-19 07:00AM  
Dec-11-19 05:09PM  
Dec-06-19 07:43AM  
Nov-19-19 07:00AM  
Nov-18-19 07:00AM  
Nov-07-19 10:00AM  
Nov-05-19 04:01PM  
Oct-31-19 12:15PM  
Oct-23-19 12:18PM  
Oct-10-19 08:41AM  
Sep-23-19 07:30AM  
Sep-16-19 07:30AM  
Sep-13-19 07:48PM  
Sep-10-19 07:30AM  
Aug-26-19 09:30AM  
Aug-13-19 10:01AM  
Aug-08-19 12:51PM  
Aug-07-19 07:30AM  
Aug-05-19 08:00AM  
Jul-31-19 12:12PM  
Jul-17-19 07:30AM  
Jun-24-19 04:01PM  
Jun-20-19 08:36AM  
07:25AM  
Jun-19-19 04:01PM  
Jun-10-19 08:00AM  
Jun-06-19 04:27PM  
01:34PM  
12:30PM  
May-27-19 11:10AM  
May-21-19 12:50PM  
May-19-19 09:29PM  
May-09-19 02:50PM  
07:00AM  
May-02-19 10:30AM  
Apr-22-19 09:37AM  
Apr-15-19 01:15PM  
Apr-11-19 02:45PM  
12:07PM  
Mar-27-19 09:00AM  
Mar-26-19 12:11PM  
Mar-20-19 12:19PM  
Mar-12-19 11:35PM  
Mar-08-19 11:39AM  
07:00AM  
Mar-05-19 09:08AM  
Feb-26-19 04:02PM  
Feb-20-19 04:00PM  
Feb-19-19 07:00AM  
Feb-14-19 08:40AM  
Feb-13-19 11:12AM  
Feb-04-19 07:00AM  
Jan-03-19 01:08PM  
Dec-20-18 02:54PM  
Dec-19-18 05:37AM  
Dec-17-18 08:39PM  
Nov-20-18 07:00AM  
Nov-19-18 07:00AM  
Nov-08-18 07:00AM  
Oct-18-18 11:49AM  
Oct-16-18 06:16PM  
Sep-24-18 07:00AM  
Aug-07-18 04:01PM  
Jul-18-18 07:30AM  
Jul-17-18 07:30AM  
Jun-25-18 04:20PM  
Jun-18-18 07:30AM  
Jun-11-18 07:30AM  
Jun-08-18 11:00AM  
May-10-18 04:01PM  
May-01-18 01:27PM  
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Williams Gregory C.CHIEF EXECUTIVE OFFICERJul 30Option Exercise0.001,87508,083Jul 31 04:10 PM
Belloff Neil S.COO, GENERAL COUNSEL &CORP SECJul 30Option Exercise0.001,56306,750Jul 31 04:10 PM